Be sure to read this very interesting story in the Pasadena Star News by Dr. Claire Panosian Dunavan, an infectious disease specialist and a professor of medicine at the David Geffen School of Medicine at UCLA and a resident of Pasadena.
Her story is written as a comment on the new Food Reform Bill just passed by both Houses, and points out that “reducing food-borne illness to the lowest possible levels also requires consumer education and collaboration. Above all, consumers with underlying disease need to go the extra mile to protect themselves. Why? Statistically and biologically, they are the ones with the worst outcomes from food-borne blights.”
To illustrate her point she discusses the case of a women who ate infected oysters and what happened to her and others.
Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.
The study was published in the January 2010 issue (Volume 92, Part 1) of the Journal of General Virology.
A researcher and his team with the University of Alberta Faculty of Medicine & Dentistry have discovered a new class of drugs that could one day be used to treat people with hepatitis B. They have also made a similar discovery for the treatment of tuberculosis.
Working with cultures in his lab, Rakesh Kumar and his colleagues have discovered a new class of drugs for hepatitis B that does three important things: it is effective against the normal strain of the hepatitis B virus, it is effective against the drug-resistant strain and it isn’t toxic to healthy cells. He says no one else in the world has identified this class of drugs. These new drugs could be used in combination with other hepatitis B drugs on the market – at the same time, by themselves or one after the other.
Hundreds of doctors, politicians, researchers and frontline workers gathered with drug users and ex-users in Austin, Texas, last month to openly talk about drug use. But instead of reaffirming their commitment to the decades-long war on drugs, the eighth National Harm Reduction Conference featured discussions on opening needle exchanges, legalizing and regulating the drug trade, and overdose prevention methods.
BERKELEY, CA — (MARKET WIRE) — 12/23/10 — Dynavax Technologies Corporation (NASDAQ: DVAX) today reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine. The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection. The Phase 1b data showed:
All doses were generally safe and well tolerated; and
Individual immunologic and virologic responses were observed across cohorts at all dose levels.
No conclusions regarding the potential clinical impact of the therapy could be reached in this small study. Dynavax’s treatment approach combines both the surface and core hepatitis B virus (HBV) antigens with ISCOMATRIX® adjuvant originally entered into development by Rhein Biotech prior to its acquisition by Dynavax in 2006. The candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information, visit www.dynavax.com.
ISCOMATRIX® is a registered trademark of CSL Behring
The UAE Ministry of Health has issued a warning advising against the use of fish pedicures, saying people who use them could contract serious diseases, such as HIV and hepatitis.
Dr Amin Al Amiri, Assistant Undersecretary for Medical Practices and Licences at the ministry, told the Dubai-based Khaleej Times: “The use of these fish pose a health threat, because it may cause the spread of several diseases, and the viral infections such as hepatitis and even HIV/Aids.”
Nanogen, a Vietnamese company which makes drugs for the cure of Hepatitis B, has produced a drug for Hepatitis C in an injection form – Pegnano.
However Hoffmann-La Roche AG, which holds the patent for Peginterferon alfa 2a in Vietnam, contests this. Roche holds the patent until 2017.
When Roche complained at first the Vietnamese government upheld Roche’s patent but later reversed the decision.
Nanogen Biopharmaceutical spent 9 years making the drug accessible to poor Vietnamese hepatitis patients. Pegnano is sold for VND1.5 million-1.9 million per 180mcg (USD77); Roche’s price is VND4.3 million for the same amount.
Accordint to the Nanogen Company director, Ho Nhan, article 7 of the Vietnamese Intellectual Property Law was revised in 2009 and clearly stated that the government can ban or limit the exercise of intellectual rights in cases where such rights harm national defense, welfare of the people or affects other crucial national interests.